Licensing status

Publication and contact information

Infectious disease


Angiopoietin 2 (ANG2; ANGPT2)

Mouse studies suggest inhibiting ANG2 could help treat sepsis. ANG2 is upregulated during sepsis. In mice, endothelium-specific ANG2 overexpression increased microvascular disturbances, hypotension and dilatory cardiomyopathy compared with normal expression. In a mouse model for sepsis, two ANG2-targeting antibodies attenuated microvascular and cardiac deterioration and decreased mortality compared with a control antibody. Next steps include testing the antibodies in additional mouse models and larger animal models of sepsis.
Roche's RG7221, a bispecific mAb targeting VEGF and ANG2, is in Phase I testing to treat solid tumors.
Amgen Inc. and Takeda Pharmaceutical Co. Ltd. have trebananib, a recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins, in Phase III or earlier testing for various cancers.
Silence Therapeutics plc has Atu111, a small interfering RNA lipoplex against ANG2, in preclinical development to treat sepsis.
At least three other companies have ANG2-targeting compounds in Phase I testing or earlier to treat cancer or acute lung injury.

SciBX 6(30); doi:10.1038/scibx.2013.795
Published online Aug. 8, 2013

Antibodies patented by Roche for treatment of cancer, vascular disease and retinopathies; licensing status unavailable

Ziegler, T. et al. J. Clin. Invest.;
published online July 1, 2013;
Contact: Christian Kupatt, Klinikum Grosshadern of the Ludwig Maximilians University, Munich, Germany